Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
based on the clinical study FENOC, indicated that there is no significant difference in efficacy AICC and Eptacog alfa therapy in patients susceptible to this treatment. An analysis of the direct and indirect costs shows that the costs of the annual course of treatment of 142 patients in Russia are...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Russo |
| 出版事項: |
IRBIS LLC
2015-03-01
|
| シリーズ: | Фармакоэкономика |
| 主題: | |
| オンライン･アクセス: | https://www.pharmacoeconomics.ru/jour/article/view/44 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|